Metraipolis › archive › dc_9b4646fa3601

Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience — Europe PMC PMID:41375032

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41375032
DOI
10.3390/cancers17233834
License (as archived)
solo-consultazione
Archived
2026-11-08T04:10:04.670Z
SHA-256 of the archived text
eea7dc987bfcc1731a501e00d135ae3a9156839ddebd162fd4776e4b6d8e0a52
Stable URL of this page
https://metraipolis.com/documento/dc_9b4646fa3601

How to cite

Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience — Europe PMC PMID:41375032 — Europe PMC (en), https://europepmc.org/article/MED/41375032 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9b4646fa3601 (Metraipolis archive dc_9b4646fa3601, sha256 eea7dc987bfcc1731a501e00d135ae3a9156839ddebd162fd4776e4b6d8e0a52)
BibTeX
@misc{dc9b4646fa3601,
  title = {Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience — Europe PMC PMID:41375032},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41375032},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9b4646fa3601; sha256 eea7dc987bfcc1731a501e00d135ae3a9156839ddebd162fd4776e4b6d8e0a52},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41375032. Agents can read the archived copy with the MCP tool read_document.